Novartis, P&G enter agreement for OAB drug

Article

Novartis Pharmaceuticals Corp. and Proctor & Gamble Pharmaceuticals, Inc. have entered into an agreement for the co-promotion and further development of darifenacin (Enablex) extended-release tablets for the treatment of overactive bladder in the United States.

Novartis Pharmaceuticals Corp. and Proctor & Gamble Pharmaceuticals, Inc. have entered into an agreement for the co-promotion and further development of darifenacin (Enablex) extended-release tablets for the treatment of overactive bladder in the United States. Novartis will continue to record revenues for the drug and will pay royalties to Proctor & Gable based on the product's performance.

In related news, Indevus Pharmaceuticals, Inc. has announced the closing of a previously announced sale of the marketing rights for trospium chloride (Sanctura) from Odyssey Pharmaceuticals, Inc. to Esprit Pharma Holding Co., Inc. Esprit Pharma is a recently formed, privately held pharmaceutical company.

Related Videos
Doctor consulting patient | Image Credit: © Liudmila Dutko - stock.adobe.com
Daniel J. Heidenberg, MD, answers a question during a Zoom video interview
African American patient explaining issues to Asian doctor using tablet | Image Credit: © rocketclips - stockadobe.com
Todd M. Morgan, MD, answers a question during a Zoom video interview
3D illustration of prostate cancer cells | Image Credit: © Dr_Microbe - stock.adobe.com
Group of doctors reading a document | Image Credit: © Flamingo Images - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.